dc.contributor.author |
Falcon-Neyra, Lola |
dc.contributor.author |
Palladino, Claudia |
dc.contributor.author |
Navarro Gómez, María Luisa |
dc.contributor.author |
Soler-Palacín, Pere |
dc.contributor.author |
González-Tomé, María Isabel |
dc.contributor.author |
De Ory, Santiago J. |
dc.contributor.author |
Frick, Marie Antoinette |
dc.contributor.author |
Fortuny Guasch, Claudia |
dc.contributor.author |
Noguera-Julian, Antoni |
dc.contributor.author |
Moreno, Elena Bermúdez |
dc.contributor.author |
Santos, Juan Luis |
dc.contributor.author |
Olbrich, Peter |
dc.contributor.author |
López-Cortés, Luis F. |
dc.contributor.author |
Briz, Verónica |
dc.contributor.author |
Neth, Olaf |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2016 |
dc.identifier |
https://ddd.uab.cat/record/185901 |
dc.identifier |
urn:10.1097/MD.0000000000003842 |
dc.identifier |
urn:oai:ddd.uab.cat:185901 |
dc.identifier |
urn:pmid:27310962 |
dc.identifier |
urn:pmcid:PMC4998448 |
dc.identifier |
urn:pmc-uid:4998448 |
dc.identifier |
urn:scopus_id:84976351380 |
dc.identifier |
urn:wos_id:000378053000022 |
dc.identifier |
urn:altmetric_id:10353155 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/84dfff8e-d8ba-4bd5-b601-08264da5462f |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:4998448 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Instituto de Salud Carlos III CP13-00098 |
dc.relation |
Instituto de Salud Carlos III RD06-006 |
dc.relation |
Instituto de Salud Carlos III RD12-0017-0035 |
dc.relation |
Instituto de Salud Carlos III RD12-0017-0037 |
dc.relation |
Instituto de Salud Carlos III MPY 1039-14 |
dc.relation |
Medicine ; Vol. 95 (june 2016) |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Adolescents |
dc.subject |
Antiretroviral therapy |
dc.subject |
Children |
dc.subject |
HIV-1 |
dc.subject |
Rilpivirine |
dc.title |
Off-label use of rilpivirine in combination with emtricitabine and tenofovir in HIV-1-infected pediatric patients |
dc.type |
Article |
dc.description.abstract |
Altres ajuts: Financial support was provided by FIPSE (grant number: 36-0910-10). CP is supported by the Portuguese Fundação para a Ciência e Tecnologia (FCT) (grant number SFRH/BPD/77448/2011, part of the EDCTP2 program supported by the European Union). |
dc.description.abstract |
To assess the safety and efficacy of rilpivirine in combination with emtricitabine and tenofovir (RPV/FTC/TDF) as a once-daily single-tablet regimen (STR) in HIV-1-infected children and adolescents we performed a multicenter case series study of HIV-1-infected patients. Inclusion criteria were initiation of therapy with RPV/FTC/TDF before the age of 18. Patients were divided into undetectable viral load (uVL) group, HIV-1 RNA < 20 copies/mL on stable combined antiretroviral therapy (cART), and detectable viral load (dVL) group, HIV-1 RNA ≥ 20 copies/mL at RPV/FTC/TDF initiation. Patients were monitored from the date of RPV/FTC/TDF initiation until June 30, 2015, RPV/FTC/TDF discontinuation or failure to follow-up. Seventeen patients (8 in uVL and 9 in dVL group) with age between 11.6 and 17.6 were included. Reasons for switching were toxicity (n = 4) and simplification (n = 4) in uVL; viral failure (n = 8) and cART initiation (n = 1) in the dVL group. After a median follow-up of 90 (uVL) and 40 weeks (dVL), 7/8 (86%) patients maintained and 8/9 (89%) achieved and maintained HIV-1 suppression. Median CD4 count increased from 542 to 780/μL (uVL, P = 0.069) and 480 to 830/μL (dVL, P = 0.051). Five patients (2 in uVL and 3 in dVL) improved their immunological status from moderate to no immunosuppression. Serum lipid profiles improved in both groups; cholesterol dropped significantly in the dVL group (P = 0.008). Grade 1 laboratory adverse events (AEs) were observed in 3 patients. No clinical AEs occurred. Adherence was complete in 9 patients (5 in uVL and 4 in dVL); 1 adolescent interrupted treatment. Once-daily STR with RPV/FTC/TDF may be a safe and effective choice in selected HIV-1-infected adolescents and children. |